pharma · Contraception · Chlamydia Trachomatis Infection · EVFM
Evofem Biosciences
Evofem Biosciences patent portfolio — 8 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- San Diego, USA
- Founded
- 2015
- Employees
- 39
- Programs
- 6
- Drugs
- 2
- Patents
- 8
Evofem Biosciences patents
8 pharmaceutical patents indexed for Evofem Biosciences. 0 expire within 24 months.
Evofem Biosciences has 8 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12280037
Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof
granted -
US 12172969
Deuterated secnidazole for use in the treatment of bacterial vaginosis and methods and uses thereof
granted -
US 11992472
Compositions and methods for enhancing the efficacy of contraceptive microbicides
granted -
US 11439610
Compositions and methods for enhancing the efficacy of contraceptive microbicides
granted -
US 11419835
Method of treatment and prevention of bacterial vaginosis
granted -
US 11337989
Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound
granted -
US 10568855
Compositions and methods for enhancing the efficacy of contraceptive microbicides
granted -
US 9566232
Compositions and methods for enhancing the efficacy of contraceptive microbicides
granted
Frequently asked questions
How many patents does Evofem Biosciences have?
8 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Evofem Biosciences patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.